

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>PERCEPTIVE ADVISORS LLC</u>  (Last) (First) (Middle) 51 ASTOR PLACE, 10TH FLOOR  (Street) NEW YORK NY 10003  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 09/17/2020	3. Issuer Name and Ticker or Trading Symbol <u>Athira Pharma, Inc.</u> [ <u>ATHA</u> ]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person  <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	411,196	I	See footnote <sup>(1)</sup>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Preferred Stock	(2)	(2)	Common Stock	1,644,785	(2)	I	See footnote <sup>(1)</sup>
Stock Options (Right to Buy)	(3)	09/16/2030	Common Stock	27,742	17	I	See footnote <sup>(4)</sup>

1. Name and Address of Reporting Person\*  
PERCEPTIVE ADVISORS LLC  
  
 (Last) (First) (Middle)  
 51 ASTOR PLACE, 10TH FLOOR  
  
 (Street)  
 NEW YORK NY 10003  
  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD  
  
 (Last) (First) (Middle)  
 C/O PERCEPTIVE ADVISORS LLC  
 51 ASTOR PLACE, 10TH FLOOR  
  
 (Street)  
 NEW YORK NY 10003  
  
 (City) (State) (Zip)

(City)

(State)

(Zip)

**Explanation of Responses:**

1. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. The Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Joseph Edelman, the managing member of the Advisor, serves as a director of the Issuer and has filed a separate Form 3.
2. The Series B Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1-for-1 basis, and will automatically convert to shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.
3. One-thirty-sixth of the shares subject to the option will vest on October 17, 2020 and thereafter one-thirty-sixth of the shares subject to the option will vest each month.
4. Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Edelman in connection with his role as a member of the Issuer's board of directors. The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase common stock of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Edelman's board service through a partial management fee offset. The Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

**Remarks:**

/s/ Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager By: Joseph Edelman, its managing member  
/s/ Perceptive Advisors LLC, By: Joseph Edelman, its managing member  
 \*\* Signature of Reporting Person                      Date                      09/17/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**